Upcoming Login Downtime
We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.
For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Kiniksa Pharmaceuticals Ltd.
Industry Sector: HealthTechnology
CEO: Sanj K. Patel
Number Of Employees: 315
Enterprise Value: $1,178,997,865
PE Ratio: -36.59
Exchange/Ticker 1: NASDAQ:KNSA
Exchange/Ticker 2: N/A
Latest Market Cap: $1,609,795,584
BioCentury | Aug 1, 2023
Deals
Pharma deals seek novelty with heavy focus on first in class
An analysis of the products, technologies and targets that have attracted global pharma deals over past 12 months
BioCentury | Jul 26, 2023
Finance
July 25 Quick Takes: Biogen cutting 1,000 jobs
Plus: Stoke falls on Dravet update and updates from Astellas-PeptiDream, Kiniksa and A-Alpha
BioCentury | Nov 14, 2022
Data Byte
A snapshot of the GM-CSF pipeline
GSK’s decision to drop otilimab brings other GM-CSF therapies under focus
BioCentury | Aug 5, 2022
Finance
Surge of positive sentiment lifts biotech shares
Alnylam readout, wave of dealmaking led by Amgen deliver gains in indexes
BioCentury | Aug 3, 2022
Deals
Pair of Roche deals add allogeneic cell therapies, first-in-class fibrosis molecule
Deals provide substantial cash runway extensions for Poseida, Kiniksa
BioCentury | May 24, 2022
Management Tracks
Ascendis names new commercial heads as Høiland retires
Plus Insmed names Wise CCO, and updates from Element,
BioCentury | Feb 23, 2022
Product Development
Feb. 22 Quick Takes: Enhertu meets mark in breast cancer subgroup
Plus updates from BeiGene, Takeda, Code, Kiniksa, Hangzhou, Homology and more
BioCentury | Dec 17, 2021
Management Tracks
Jonsson becomes COO at Nordic Nanovector
Plus: Aerie, Bio-Rad, Affinivax, Neogene, Orna and more
BioCentury | May 12, 2021
Management Tracks
Salter-Cid becomes CSO of Flagship’s new Pioneering Medicines unit; plus Veracyte, Catalent, Zoetis, Gracell, Galecto and more
Flagship Pioneering announced Luisa Salter-Cid as CSO of its new Pioneering Medicines division. Salter-Cid, a 13-year veteran of Bristol Myers Squibb Co. (NYSE:BMY), was most recently CSO at
BioCentury | Apr 21, 2021
Management Tracks
EQRx adds Rubin, Rogers to C-suite; plus Allakos, Veracyte, Translate, Sutro and more
EQRx Inc. hired Jami Rubin as CFO and Kent Rogers as chief customer officer. Rubin was partner at PJT Partners and managing director at Goldman Sachs. Rogers was SVP and chief industry relations
Items per page:
1 - 10 of 27